<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230282</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-13053</org_study_id>
    <secondary_id>31185</secondary_id>
    <secondary_id>80071</secondary_id>
    <secondary_id>HEMCLL0001</secondary_id>
    <nct_id>NCT00230282</nct_id>
  </id_info>
  <brief_title>Phase 2 Fludarabine, Cytoxan and FCCAM &lt;Alemtuzumab&gt; in Untreated B-Cell Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven E. Coutre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the safety and efficacy of the
      combination of fludarabine and cyclophosphamide in previously untreated CLL patients.
      Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day
      cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-arm study evaluated the safety and efficacy of the combination of fludarabine 25
      mg/m2/d IV and cyclophosphamide 250 mg/m2/d SC in previously untreated CLL patients.
      Participants received fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day
      cycles, followed by a no-treatment rest period (observation) for 3 to 12 weeks.

      Responders entered a no-treatment rest period (observation) for 3 to 8 weeks, then depending
      on status, continued on follow-up or on-study to receive Campath stating at 3 mg/day with the
      dose adjusted to the maximum tolerated dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response criteria as per the NCI-WG Revised Guidelines for B-CLL
Complete remission:
No lymphadenopathy by physical exam No hepatomegaly or splenomegaly Absence of constitutional symptoms Polymorphonuclear leukocytes &gt; 1,500/uL, Platelets &gt; 100,000/uL, Hemoglobin &gt; 11.0 g/dL Bone marrow aspirate and biopsy normocellular with &lt; 30% lymphocytes Absent lymphoid nodules
Partial remission:
50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value
50% reduction in lymphadenopathy and/or ≥ 50% reduction in the size of the liver and/or spleen AND one or more of the following Polymorphonuclear leukocytes &gt; 1,500/uL or 50% improvement over baseline Platelets &gt; 100,000/uL or 50% improvement over baseline Hemoglobin &gt; 11.0 g/dL or 50% improvement over baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>105 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Leukemia</condition>
  <condition>B-cell Leukemia</condition>
  <condition>Chronic Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Fludarabine, cytoxan, then alemtuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>3 to 30 mg, IV</description>
    <arm_group_label>Fludarabine, cytoxan, then alemtuzumab</arm_group_label>
    <other_name>Campath</other_name>
    <other_name>MabCampath</other_name>
    <other_name>Campath-1H</other_name>
    <other_name>Lemtrada</other_name>
    <other_name>FCCam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid</description>
    <arm_group_label>Fludarabine, cytoxan, then alemtuzumab</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoxan</intervention_name>
    <description>(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide</description>
    <arm_group_label>Fludarabine, cytoxan, then alemtuzumab</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>cytophosphane</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ age 18

          -  Karnofsky performance status 60% or above

          -  Confirmed immunohistological diagnosis of Chronic Lymphocytic Leukemia (CLL)

          -  Rai Stage I to IV as follows:

               -  Advanced stage disease (Rai Stage III or IV, or modified Rai High Risk)

               -  OR

               -  Patients with Rai Stage I - II or (Modified Rai Intermediate-Risk) disease must
                  have an indication for therapy based on 1996 NCI revised criteria for active
                  disease as follows:

                    -  Any one of the following disease-related symptoms:

                         1. Weight loss ≥ 10% body weight within the previous 6 months

                         2. Extreme fatigue

                         3. Fever greater than 100.5° F for ≥ 2 weeks without evidence of infection

                         4. Night sweats without evidence of infection

                    -  Evidence of progressive marrow failure based on the development of worsening
                       of anemia or thrombocytopenia

                    -  Autoimmune anemia and/or thrombocytopenia poorly responsive to
                       corticosteroid therapy

                    -  Massive (&gt; 6 cm below the left costal margin) or progressive splenomegaly

                    -  Bulky (&gt;10 cm in cluster) or progressive lymphadenopathy

                    -  Progressive lymphocytosis &gt; 50% increase over 2 months, or anticipated
                       doubling time &lt; 6 months

          -  Patients with immunoglobulin VH gene in unmutated nucleotide sequence configuration,
             as defined by ≥ 98% homology with the nearest germline counterpart

          -  Serum creatinine ≤ 2x the upper limit of normal

          -  Total serum bilirubin ≤ 2x the upper limit of normal.

          -  AST ≤ 2x the upper limit of normal.

          -  ALT ≤ 2x the upper limit of normal.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Prior pharmacological treatment for CLL

          -  Past history of anaphylaxis following exposure to monoclonal antibodies

          -  Active secondary malignancy or a history of malignant disease (other than CLL or
             non-melanoma skin cancer) within the preceding 5 years

          -  Any medical condition requiring systemic corticosteroids

          -  Active systemic infection

          -  Major systemic or other illness (including Coombs positivity and active hemolysis)
             that would, in the opinion of the investigator, interfere with the patient's ability
             to comply with the protocol, compromise patient safety, or interfere with the
             interpretation of study results

          -  HIV positive by serologic testing

          -  Pregnant or nursing female

          -  Unwilling/unable to practice an acceptable form of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Edward Coutre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <results_first_submitted>August 27, 2014</results_first_submitted>
  <results_first_submitted_qc>August 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2014</results_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Steven E. Coutre</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine and Cyclophosphamide, Followed by Alemtuzumab</title>
          <description>Fludarabine 25 mg/m2/d IV and cyclophosphamide 250 mg/m2/d SC on days 1 to 3 for each of six 28-day cycles, when the assessment for Primary Completion occurred. Responders entered a no-treatment rest period (observation) for 3 to 8 weeks, then depending on status, continued on follow-up or on-study to receive alemtuzumab IV starting at 3 mg/day with the dose adjusted to the maximum tolerated dose (up to 30 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Fludarabine + Cyclophosphamide</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Richters transformation (progression)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintanence Therapy With Alemtuzumab</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine and Cyclophosphamide, Followed by Alemtuzumab</title>
          <description>Fludarabine 25 mg/m2/d IV and cyclophosphamide 250 mg/m2/d SC on days 1 to 3 for each of six 28-day cycles, when the assessment for Primary Completion occurred. Responders entered a no-treatment rest period (observation) for 3 to 8 weeks, then depending on status, continued on follow-up or on-study to receive alemtuzumab IV starting at 3 mg/day with the dose adjusted to the maximum tolerated dose (up to 30 mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)</title>
        <description>Response criteria as per the NCI-WG Revised Guidelines for B-CLL
Complete remission:
No lymphadenopathy by physical exam No hepatomegaly or splenomegaly Absence of constitutional symptoms Polymorphonuclear leukocytes &gt; 1,500/uL, Platelets &gt; 100,000/uL, Hemoglobin &gt; 11.0 g/dL Bone marrow aspirate and biopsy normocellular with &lt; 30% lymphocytes Absent lymphoid nodules
Partial remission:
50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value
50% reduction in lymphadenopathy and/or ≥ 50% reduction in the size of the liver and/or spleen AND one or more of the following Polymorphonuclear leukocytes &gt; 1,500/uL or 50% improvement over baseline Platelets &gt; 100,000/uL or 50% improvement over baseline Hemoglobin &gt; 11.0 g/dL or 50% improvement over baseline</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine and Cyclophosphamide, Followed by Alemtuzumab</title>
            <description>Fludarabine 25 mg/m2/d IV and cyclophosphamide 250 mg/m2/d SC on days 1 to 3 for each of six 28-day cycles, when the assessment for Primary Completion occurred. Responders entered a no-treatment rest period (observation) for 3 to 8 weeks, then depending on status, continued on follow-up or on-study to receive alemtuzumab IV starting at 3 mg/day with the dose adjusted to the maximum tolerated dose (up to 30 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)</title>
          <description>Response criteria as per the NCI-WG Revised Guidelines for B-CLL
Complete remission:
No lymphadenopathy by physical exam No hepatomegaly or splenomegaly Absence of constitutional symptoms Polymorphonuclear leukocytes &gt; 1,500/uL, Platelets &gt; 100,000/uL, Hemoglobin &gt; 11.0 g/dL Bone marrow aspirate and biopsy normocellular with &lt; 30% lymphocytes Absent lymphoid nodules
Partial remission:
50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value
50% reduction in lymphadenopathy and/or ≥ 50% reduction in the size of the liver and/or spleen AND one or more of the following Polymorphonuclear leukocytes &gt; 1,500/uL or 50% improvement over baseline Platelets &gt; 100,000/uL or 50% improvement over baseline Hemoglobin &gt; 11.0 g/dL or 50% improvement over baseline</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>105 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine and Cyclophosphamide, Followed by Alemtuzumab</title>
            <description>Fludarabine 25 mg/m2/d IV and cyclophosphamide 250 mg/m2/d SC on days 1 to 3 for each of six 28-day cycles, when the assessment for Primary Completion occurred. Responders entered a no-treatment rest period (observation) for 3 to 8 weeks, then depending on status, continued on follow-up or on-study to receive alemtuzumab IV starting at 3 mg/day with the dose adjusted to the maximum tolerated dose (up to 30 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="12" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine, Cytoxan, Then Alemtuzumab</title>
          <description>Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
Alemtuzumab: 3 to 30 mg, IV
Fludarabine: [(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid
Cytoxan: (RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <description>G3; hospitalization after 4th cycle. Resolved with empiric antibiotics.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <description>G3; required transfusion. Pre-existing AIHA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>hemolysis</sub_title>
                <description>G3. Pre-existing AIHA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>lung infection</sub_title>
                <description>G3 Hospitalized. Received IV antibiotics with resolution.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <description>G3 Required brief course of oxygen therapy</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>G3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis</sub_title>
                <description>G3 Oral mucositis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven E. Coutre, Associate Professor of Medicine</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-6661</phone>
      <email>coutre@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

